What one share of Cerenome holds
Plus Therapeutics is a U.S. healthcare company developing and commercializing precision diagnostics and targeted radiopharmaceuticals for central nervous system (“CNS”) cancers. CNSide Diagnostics, LLC (“CNSide Diagnostics”) is our wholly owned subsidiary that develops and commercializes proprietary laboratory-developed tests, such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas.
Cerenome’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.70 |
|---|---|
| Profit | −$4.36 |
| Capex (buildings and equipment) | $0.23 |
| Free cash flow | −$3.94 |
| Cash and investments | $0.32 |
| Book value | $0.75 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$697.94 | — | — | — | $168.41 |
| 2021 | — | −$415.63 | — | — | — | $261.99 |
| 2022 | — | −$289.58 | — | — | — | $71.93 |
| 2023 | $39.10 | −$105.99 | $1.27 | −$103.56 | — | −$7.58 |
| 2024 | $18.91 | −$58.52 | $0.47 | −$34.74 | — | −$37.94 |
| 2025 | $1.68 | −$7.19 | $0.02 | −$6.70 | — | $0.72 |
Common questions about Cerenome
How much does one share of Cerenome earn?
Over the last 12 months, Cerenome lost $4.36 for each share on $0.70 of sales.
Does Cerenome pay a dividend?
Cerenome didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Cerenome’s book value per share?
Cerenome’s book value is $0.75 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Cerenome have?
Each share of Cerenome has $0.32 of cash and investments, as of June 30, 2026.
What is Cerenome’s free cash flow per share?
−$3.94 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Cerenome bought back shares?
Cerenome’s share count rose about 26258% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.